TY - JOUR
T1 - Blood coagulation and beyond
T2 - Position paper from the Fourth Maastricht Consensus Conference on Thrombosis
AU - Akbulut, Asim Cengiz
AU - Arisz, Ryanne A.
AU - Baaten, Constance C.F.M.J.
AU - Baidildinova, Gaukhar
AU - Barakzie, Aarazo
AU - Bauersachs, Rupert
AU - Berg, Jur ten
AU - van den Broek, Wout W.A.
AU - Boer, H. C.de
AU - Bonifay, Amandine
AU - Bröker, Vanessa
AU - Buka, Richard J.
AU - Cate, Hugo ten
AU - Cate-Hoek, Arina J.ten
AU - Cointe, S.
AU - Luca, C. De
AU - Simone, Ilaria De
AU - Diaz, Rocio Vacik
AU - Dignat-George, Françoise
AU - Freson, Kathleen
AU - Gazzaniga, Giulia
AU - van Gorp, Eric C.M.
AU - Habibi, Anxhela
AU - Henskens, Yvonne M.C.
AU - Iding, Aaron F.J.
AU - Khan, Abdullah
AU - Koenderink, Gijsje H.
AU - Konkoth, Akhil
AU - Lacroix, Romaric
AU - Lahiri, Trisha
AU - Lam, Wilbur
AU - Lamerton, Rachel E.
AU - Lorusso, Roberto
AU - Luo, Qi
AU - Maas, Coen
AU - Mccarty, Owen J.T.
AU - van der Meijden, Paola E.J.
AU - Meijers, Joost C.M.
AU - Mohapatra, Adarsh K.
AU - Nevo, Neta
AU - Robles, Alejandro Pallares
AU - Poncelet, Philippe
AU - Reinhardt, Christoph
AU - Ruf, Wolfram
AU - Saraswat, Ronald
AU - Schönichen, Claudia
AU - Schutgens, Roger
AU - Simioni, Paolo
AU - Spada, Stefano
AU - Spronk, Henri M.H.
AU - Tazhibayeva, Karlygash
AU - Thachil, Jecko
AU - Vallier, L.
AU - Veninga, Alicia
AU - Verhamme, Peter
AU - Visser, Chantal
AU - Watson, Steve P.
AU - Wenzel, Philip
AU - Willems, Ruth A.L.
AU - Willers, Anne
AU - Zhang, Pengyu
AU - Zifkos, Konstantinos
AU - Zonneveld, Anton Jan van
N1 - Publisher Copyright:
© 2023. The Author(s).
PY - 2023/5/12
Y1 - 2023/5/12
N2 - The Fourth Maastricht Consensus Conference on Thrombosis included the following themes. Theme 1: The coagulome as a critical driver of cardiovascular disease. Blood coagulation proteins also play divergent roles in biology and pathophysiology, related to specific organs, including brain, heart, bone marrow, and kidney. Four investigators shared their views on these organ-specific topics. Theme 2: Novel mechanisms of thrombosis. Mechanisms linking factor XII to fibrin, including their structural and physical properties, contribute to thrombosis, which is also affected by variation in microbiome status. Virus infection-associated coagulopathies perturb the hemostatic balance resulting in thrombosis and/or bleeding. Theme 3: How to limit bleeding risks: insights from translational studies. This theme included state-of-the-art methodology for exploring the contribution of genetic determinants of a bleeding diathesis; determination of polymorphisms in genes that control the rate of metabolism by the liver of P2Y12 inhibitors, to improve safety of antithrombotic therapy. Novel reversal agents for direct oral anticoagulants are discussed. Theme 4: Hemostasis in extracorporeal systems: the value and limitations of ex vivo models. Perfusion flow chamber and nanotechnology developments are developed for studying bleeding and thrombosis tendencies. Vascularized organoids are utilized for disease modeling and drug development studies. Strategies for tackling extracorporeal membrane oxygenation-associated coagulopathy are discussed. Theme 5: Clinical dilemmas in thrombosis and antithrombotic management. Plenary presentations addressed controversial areas, i.e., thrombophilia testing, thrombosis risk assessment in hemophilia, novel antiplatelet strategies, and clinically tested factor XI(a) inhibitors, both possibly with reduced bleeding risk. Finally, COVID-19-associated coagulopathy is revisited.
AB - The Fourth Maastricht Consensus Conference on Thrombosis included the following themes. Theme 1: The coagulome as a critical driver of cardiovascular disease. Blood coagulation proteins also play divergent roles in biology and pathophysiology, related to specific organs, including brain, heart, bone marrow, and kidney. Four investigators shared their views on these organ-specific topics. Theme 2: Novel mechanisms of thrombosis. Mechanisms linking factor XII to fibrin, including their structural and physical properties, contribute to thrombosis, which is also affected by variation in microbiome status. Virus infection-associated coagulopathies perturb the hemostatic balance resulting in thrombosis and/or bleeding. Theme 3: How to limit bleeding risks: insights from translational studies. This theme included state-of-the-art methodology for exploring the contribution of genetic determinants of a bleeding diathesis; determination of polymorphisms in genes that control the rate of metabolism by the liver of P2Y12 inhibitors, to improve safety of antithrombotic therapy. Novel reversal agents for direct oral anticoagulants are discussed. Theme 4: Hemostasis in extracorporeal systems: the value and limitations of ex vivo models. Perfusion flow chamber and nanotechnology developments are developed for studying bleeding and thrombosis tendencies. Vascularized organoids are utilized for disease modeling and drug development studies. Strategies for tackling extracorporeal membrane oxygenation-associated coagulopathy are discussed. Theme 5: Clinical dilemmas in thrombosis and antithrombotic management. Plenary presentations addressed controversial areas, i.e., thrombophilia testing, thrombosis risk assessment in hemophilia, novel antiplatelet strategies, and clinically tested factor XI(a) inhibitors, both possibly with reduced bleeding risk. Finally, COVID-19-associated coagulopathy is revisited.
UR - http://www.scopus.com/inward/record.url?scp=85161042984&partnerID=8YFLogxK
U2 - 10.1055/a-2052-9175
DO - 10.1055/a-2052-9175
M3 - Article
C2 - 36913975
AN - SCOPUS:85161042984
SN - 0340-6245
VL - 123
SP - 808
EP - 839
JO - Thrombosis and Haemostasis
JF - Thrombosis and Haemostasis
IS - 8
ER -
